– Results highlight PPMP as a tool for identifying most promising drug combinations for patients in high unmet medical needs, including JMML – JMML is a rare, aggressive pediatric malignancy for which ...
Bottom Line: The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a phase II ...
Phase II/III Trial of Etoposide and High-Dose Ifosfamide in Newly Diagnosed Metastatic Osteosarcoma: A Pediatric Oncology Group Trial PURPOSE: We report the first large prospective study of children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results